Literature DB >> 19562493

Influence of tumor stage, symptoms, and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer.

Miquel Porta1, José Pumarega, Tomàs López, Manuel Jariod, Esther Marco, Joan O Grimalt.   

Abstract

BACKGROUND: Knowledge is scant on the relationships between pathophysiologic processes common during cancer progression and changes in blood concentrations of organochlorine compounds (OCs).
OBJECTIVE: To analyze the influence of tumor stage, cancer symptoms, and time of blood extraction on serum concentrations of OCs in exocrine pancreatic cancer (EPC).
METHODS: Subjects were 144 incident cases of EPC prospectively recruited in eastern Spain. Blood was drawn and face-to-face interviews with patients were conducted during hospital admission. Information on signs and symptoms was obtained from medical records and patient interviews. OCs were analyzed by high-resolution gas chromatography with electron-capture detection. General linear models were applied to analyze log-transformed OCs corrected for total lipids.
RESULTS: Lower concentrations of six of the seven OCs analyzed (p,p'-DDE, three polychlorinated biphenyls, hexachlorobenzene, and β-hexachlorocyclohexane) were observed in patients with cholestatic syndrome (jaundice, hypocholia, and choluria). The constitutional syndrome increased only p,p'-DDT. The lowering effect of the cholestatic syndrome was stronger than the increasing effect of the constitutional syndrome (fatigue, anorexia, and weight loss), except for p,p'-DDT. When symptoms were considered, stage had only weakly inverse relationships with OC levels. The effects of symptoms on p,p'-DDE, p,p'-DDT, and the three PCBs remained significant after adjusting by the interval from blood extraction to first symptom of EPC, and even when further adjusting by stage.
CONCLUSIONS: Restriction or adjustment by stage and timing of blood draw may be insufficient to prevent biases associated with cancer progression. Symptoms may enable investigators to assess disease-induced changes in lipophilic exposure biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562493     DOI: 10.1007/s10552-009-9383-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  8 in total

1.  STrengthening the reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement.

Authors:  Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B Farmer; John P A Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H Phillips; Bernadette Schoket; Ulf Stromberg; Roel Vermeulen; Christopher Wild; Miquel Porta; Paolo Vineis
Journal:  Eur J Epidemiol       Date:  2011-10-29       Impact factor: 8.082

2.  Urinary pH, cigarette smoking and bladder cancer risk.

Authors:  Juan Alguacil; Manolis Kogevinas; Debra T Silverman; Núria Malats; Francisco X Real; Montserrat García-Closas; Adonina Tardón; Manuel Rivas; Montserrat Torà; Reina García-Closas; Consol Serra; Alfredo Carrato; Ruth M Pfeiffer; Joan Fortuny; Claudine Samanic; Nathaniel Rothman
Journal:  Carcinogenesis       Date:  2011-03-14       Impact factor: 4.944

3.  Adjusting serum concentrations of organochlorine compounds by lipids and symptoms: a causal framework for the association with K-ras mutations in pancreatic cancer.

Authors:  Tomàs López; José A Pumarega; Anna Z Pollack; Duk-Hee Lee; Lorenzo Richiardi; David R Jacobs; Enrique F Schisterman; Miquel Porta
Journal:  Chemosphere       Date:  2014-05-20       Impact factor: 7.086

4.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.

Authors:  Lucy A Parker; Miquel Porta; Blanca Lumbreras; Tomàs López; Luisa Guarner; Ildefonso Hernández-Aguado; Alfredo Carrato; Josep M Corominas; Juli Rifà; Esteve Fernandez; Joan Alguacil; Núria Malats; Francisco X Real
Journal:  Eur J Epidemiol       Date:  2011-02-06       Impact factor: 8.082

5.  Methodological deficits in diagnostic research using '-omics' technologies: evaluation of the QUADOMICS tool and quality of recently published studies.

Authors:  Lucy A Parker; Noemí Gómez Saez; Blanca Lumbreras; Miquel Porta; Ildefonso Hernández-Aguado
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

6.  STrengthening the Reporting of OBservational studies in Epidemiology--Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement.

Authors:  Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B Farmer; John P A Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H Phillips; Bernadette Schoket; Ulf Stromberg; Roel Vermeulen; Christopher Wild; Miquel Porta; Paolo Vineis
Journal:  PLoS Med       Date:  2011-10-25       Impact factor: 11.069

7.  Assessing causal relationships in genomics: From Bradford-Hill criteria to complex gene-environment interactions and directed acyclic graphs.

Authors:  Sara Geneletti; Valentina Gallo; Miquel Porta; Muin J Khoury; Paolo Vineis
Journal:  Emerg Themes Epidemiol       Date:  2011-06-09

8.  Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.

Authors:  Miquel Porta; José Pumarega; André F S Amaral; Jeanine M Genkinger; Judit Camargo; Lorelei Mucci; Juan Alguacil; Magda Gasull; Xuehong Zhang; Eva Morales; Mar Iglesias; Shuji Ogino; Lawrence S Engel
Journal:  Environ Res       Date:  2020-06-11       Impact factor: 6.498

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.